Your browser doesn't support javascript.
loading
From Etest to Vitek 2: Impact of Enterococcal Linezolid Susceptibility Testing Methodology on Time to Active Therapy.
Nguyen, Cynthia T; Bethel, Cindy; Pettit, Natasha N; Charnot-Katsikas, Angella.
Affiliation
  • Nguyen CT; Department of Pharmacy, University of Chicago Medicine, Chicago, Illinois, USA cynthnguyen@gmail.com.
  • Bethel C; Department of Pathology, University of Chicago Medicine, Chicago, Illinois, USA.
  • Pettit NN; Department of Pharmacy, University of Chicago Medicine, Chicago, Illinois, USA.
  • Charnot-Katsikas A; Department of Pathology, University of Chicago Medicine, Chicago, Illinois, USA.
Article in En | MEDLINE | ID: mdl-32540982
ABSTRACT
Different linezolid antimicrobial susceptibility testing (AST) methodologies yield various results. In 2018, we transitioned our linezolid AST methodology from the Etest to Vitek 2. We sought to evaluate the impact of this change on antibiotic use among 181 inpatients with vancomycin-resistant enterococcal (VRE) infections. The transition from Etest to Vitek 2 resulted in an increase in linezolid susceptibility (38% versus 96%; P < 0.001) and a reduction in time to active antibiotic therapy (3 versus 2.6 days; P = 0.007).
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gram-Positive Bacterial Infections / Enterococcus Limits: Humans Language: En Journal: Antimicrob Agents Chemother Year: 2020 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gram-Positive Bacterial Infections / Enterococcus Limits: Humans Language: En Journal: Antimicrob Agents Chemother Year: 2020 Type: Article Affiliation country: United States